OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS

• US 20110009477A1
• Filed: 07/08/2010
• Published: 01/13/2011
• Est. Priority Date: 07/08/2009
• Status: Abandoned Application

• Current Assignee: Idera Pharmaceuticals, Inc. (Aceragen Incorporated)
• Original Assignee: Idera Pharmaceuticals, Inc. (Aceragen Incorporated)
• Inventors: Bhagat, Lakshmi, Kandimalla, Ekambar, Yu, Dong, Wang, Daqing, Agrawal, Sudhir
• Application Number:
  US12/832,439
• Publication Number:
  US 20110009477A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 9/0031 Rectum, anus
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides novel oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif and the use of such compounds in the prevention and treatment of TLR-medicated diseases. These oligonucleotide-based TLR antagonists containing a modified immune stimulatory motif have one or more chemical modifications in the immune stimulatory motif, which would be immune stimulatory but for the modification.

Claims

1. An oligonucleotide-based TLR antagonist containing a modified immune stimulatory motif comprising one or more modified immune stimulatory motifs, wherein CG is the modified immune stimulatory motif, wherein C is cytosine, or a pyrimidine nucleotide derivative selected from 5-methyl-dC, 2′

-O-substituted-C, 2′

-O-methyl-C, 2′

-O-methoxyethoxy-C, 2′

-O-methoxyethyl-5-methyl-C, and 2′

-O-methyl-5-methyl-C, and G is guanosine or a purine nucleotide derivative selected from 2′

-O-substituted-G, 2′

-O-methyl-G, and 2′

-O-methoxyethoxy-G;

provided that at least one C and/or G of the modified immune stimulatory motif is a specified nucleotide derivative;

wherein the modified immune stimulatory motif would be immune stimulatory but for the nucleotide derivative.

2. The oligonucleotide-based TLR antagonist according to claim 1 comprising at least two oligonucleotides linked through 3′

, 2′

, or 5′

attachments.

3. The antagonist according to claim 2 wherein the oligonucleotides are linked directly to each other at their 3′

, 2′

, or 5′

ends.

4. The antagonist according to claim 2 wherein the 3′

, 2′

, or 5′

ends of the oligonucleotide are linked to a non-nucleotidic linker.

5. The antagonist according to claim 4, wherein the linker is selected from the group consisting of Glycerol (1,2,3-Propanetriol), 1,2,4, Butanetriol, 2-(hydroxymethyl)1,4-butanediol, 1,3,5-Pentanetriol, 1,1,1-Tris(hydroxymethyl)ethane,1,1,1-Tris(hydroxymethyl)nitromethane, 1,1,1-Tris(hydroxymethyl)propane, 1,2,6-Methyl-1,3,5-pentanetriol, 1,2,3-Heptanetriol, 2-Amino-2-(hydroxymethyl)-1,3-propanediol, N[Tris(hydroxymethyl)methyl]acrylamide, cis-1,3,5-Cyclohexanetriol, Cis-1,3,5-Tri(hydroxymethyl)cyclohexane, 1,3,5-Trihydroxyl-benzene, 3,5-Di(hydroxymethyl)benzene, 1,3-Di(hydroxyethoxy)-2-hydroxyl-propane, 1,3-Di(hydroxypropoxy)-2-hydroxyl-propane, 2-Deoxy-D-ribose, 1,2,4-Trihydroxyl-benzene, D-Galactoal, 1,6-anhydro-β

-D-Glucose, 1,3,5-Tris(2-hydroxyethyl)-Cyanuric acid, Gallic acid, 3,5,7-Trihydroxyflavone, 4,6-Nitropyrogallol, Ethylene glycol, 1,3-Propanediol, 1,2-Propanediol, 1,4-Butanediol, 1,3-Butanediol, 2,3-Butanediol, 1,4-Butanediol, 1,5-Pentanediol, 2,4-Pentanediol, 1,6-Hexanediol, 1,2-Hexanediol, 1,5-Hexanediol, 2,5-Hexanediol, 1,7-Heptanediol, 1,8-Octanediol, 1,2-Octanediol, 1,9-Nonanediol, 1,12-Dodecanediol, Triethylene glycol, Tetraethylene glycol, Hexaethylene glycol, 2-(1-Aminopropyl)-1,3-propanediol, and 1,2-Dideoxyribose.

6. A pharmaceutical composition comprising the oligonucleotide according to claim 1 and a pharmaceutically acceptable carrier.

9. A method for inhibiting a TLR7- or TLR9-mediated immune response in a mammal comprising administering to a mammal an oligonucleotide-based TLR antagonist according to claim 1.

10. The method according to claim 9, wherein the route of administration is parenteral, mucosal delivery, oral, sublingual, transdermal, topical, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form.

11. A method for therapeutically treating a disease or disorder mediated by a TLR comprising administering to a mammal having the disease or disorder a therapeutically effective amount of an oligonucleotide-based TLR antagonist according to claim 1.

12. The method according to claim 11, wherein the route of administration is parenteral, mucosal delivery, oral, sublingual, transdermal, topical, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form.

13. A method for prophylactically preventing a disease or disorder mediated by a TLR comprising administering to a mammal at risk of developing the disease or disorder a prophylactically effective amount of an oligonucleotide-based TLR antagonist according to claim 1.

14. The method according to claim 13, wherein the route of administration is parenteral, mucosal delivery, oral, sublingual, transdermal, topical, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form.

15. A method for preventing cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen in a vertebrate, such method comprising administering to the vertebrate a TLR-based antagonist according to claim 1 in a pharmaceutically effective amount.

16. The method according to claim 15, wherein the TLR-based antagonist is administered in combination with one or more vaccines, antigens, antibodies, cytotoxic agents, allergens, antibiotics, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins, gene therapy vectors, DNA vaccines, adjuvants or co-stimulatory molecules.

17. The method according to claim 15, wherein the route of administration is parenteral, mucosal delivery, oral, sublingual, transdermal, topical, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form.

7. A method for modifying a TLR-stimulating oligonucleotide comprising an immune stimulatory motif, the method comprising incorporating chemical modifications into the immune stimulatory motif, wherein CG is the immune stimulatory motif and the chemical modification is selected from 5-methyl-dC, 2′

-O-substituted-C, 2′

-O-methyl-C, 2′

-O-methoxyethoxy-C, 2′

-O-methoxyethyl-5-methyl-C, 2′

-O-methyl-5-methyl-C, 2′

-O-substituted-G, 2′

-O-methyl-G, and 2′

-O-methoxyethoxy-G.

8. A method for modifying a TLR-stimulating oligonucleotide comprising an immune stimulatory motif, the method comprising incorporating chemical modifications into the immune stimulatory motif and/or to a sequence flanking the immune stimulatory motif, wherein CG is the immune stimulatory motif and the chemical modification is selected from 5-methyl-dC, 2′

-O-substituted-C, 2′

-O-methyl-C, 2′

-O-methoxyethoxy-C, 2′

-O-methoxyethyl-5-methyl-C, 2′

-O-methyl-5-methyl-C, 2′

-O-substituted-G, 2′

-O-methyl-G, and/or 2′

-O-methoxyethoxy-G.